Zoetis Inc
NYSE:ZTS

Watchlist Manager
Zoetis Inc Logo
Zoetis Inc
NYSE:ZTS
Watchlist
Price: 164.7 USD 0.26%
Market Cap: 74.3B USD
Have any thoughts about
Zoetis Inc?
Write Note

Zoetis Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zoetis Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Zoetis Inc
NYSE:ZTS
Income from Continuing Operations
$2.4B
CAGR 3-Years
7%
CAGR 5-Years
11%
CAGR 10-Years
16%
Johnson & Johnson
NYSE:JNJ
Income from Continuing Operations
$14.8B
CAGR 3-Years
-6%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Income from Continuing Operations
-$7.2B
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Income from Continuing Operations
$4.3B
CAGR 3-Years
-40%
CAGR 5-Years
4%
CAGR 10-Years
-9%
Merck & Co Inc
NYSE:MRK
Income from Continuing Operations
$12.2B
CAGR 3-Years
27%
CAGR 5-Years
5%
CAGR 10-Years
8%
Eli Lilly and Co
NYSE:LLY
Income from Continuing Operations
$8.4B
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
12%
No Stocks Found

Zoetis Inc
Glance View

Market Cap
74.4B USD
Industry
Pharmaceuticals
Economic Moat
None

In the vast panorama of the global animal health industry, Zoetis Inc. emerges as a formidable player, intricately weaving a narrative of innovation and growth. Originally part of Pfizer, Zoetis embarked on its solo journey in 2013, driven by a singular mission to understand, anticipate, and amplify the needs of both livestock and companion animals. At the heart of its operations lies an impressive pipeline of products—from vaccines and diagnostics to genetic tests and precision livestock farming software—designed to improve the health of animals. Its comprehensive approach ensures not only the well-being of the animals but also supports the burgeoning needs of veterinary practitioners and livestock producers worldwide. Financially, Zoetis masters the art of monetizing its deep-rooted expertise in animal biology and science. Revenue streams flow predominantly from the sale of these innovative products, with livestock and companion animal segments each contributing significant streams of income. The company capitalizes on its extensive global footprint, reaching customers in over 100 countries, ensuring diversified and steady cash flows. Its continued investment in R&D underscores a long-term commitment to innovation, enhancing its product offerings and driving future growth. In a world increasingly conscious of the importance of animal welfare and food security, Zoetis stands at a strategic intersection, aligning its business model with the evolving dynamics of both consumer preferences and regulatory landscapes.

ZTS Intrinsic Value
120.32 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Zoetis Inc's Income from Continuing Operations?
Income from Continuing Operations
2.4B USD

Based on the financial report for Sep 30, 2024, Zoetis Inc's Income from Continuing Operations amounts to 2.4B USD.

What is Zoetis Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
16%

Over the last year, the Income from Continuing Operations growth was 7%. The average annual Income from Continuing Operations growth rates for Zoetis Inc have been 7% over the past three years , 11% over the past five years , and 16% over the past ten years .

Back to Top